More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Headline
The White House today released its national policy framework on artificial intelligence. The framework includes several recommendations for Congress…
Headline
Registration continues for the 2026 AHA Annual Membership meeting, which will be held April 19-21 in Washington, D.C. Policymakers, legislators and thought…
Perspective
Public
Abraham Lincoln, among those whose legacy we honor with Presidents Day next week, might have put it this way: Thirteen score and three days from now… …
Headline
Capitol Hill was the focus of the second morning of the AHA 2026 Rural Health Care Leadership Conference, taking place through tomorrow in…
Headline
The AHA Feb. 10 released its 2026 Rural Advocacy Agenda, laying out the association's key priorities for Congress, the administration, regulatory agencies and…
Headline
Carmela Coyle, California Hospital Association president and CEO, announced plans Feb. 5 to retire in early 2027, according to the CHA. Coyle has been in…